Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery system

Journal of Medical Economics

Volumn 16, Issue 12, 2013, Pages 1414-1422

  Johnson, Samuel ^a,f   Delate, Thomas ^b,f   Boka, Adrian ^c   Shaw, Paul ^d,f,g   Zager, Carol ^e  

^a Clinical Pharmacy Services   (United States)

^b Pharmacy Department   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

^d Clinical Pharmacy Anticoagulation Service   (United States)

^e Kaiser Permanente Colorado   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g REGIS UNIVERSITY   (United States)

Author keywords

Cost of illness; Healthcare services; Pulmonary arterial hypertension

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; EMERGENCY CARE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PULMONARY HYPERTENSION;

AGED; COHORT STUDIES; FEMALE; HEALTH EXPENDITURES; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84889789628     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.849713     Document Type: Article

References (17)

1. Kirson NY, Birnbaum HG, Ivanova JI, et al. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 2011;27:1763-8
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619
3. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142:448-56
4. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72
5. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8
6. Falk JA, Philip KJ, Schwarz ER. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag 2010;6:273-80
7. Hrometz SL, Shields KM. Role of ambrisentan in the management of pulmonary hypertension. Ann Pharmacother 2008;42:1653-9
8. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. Chest 2010;137:376-87
9. Angalakuditi M, Edgell E, Beardsworth A, et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ 2010;13:393-402
10. Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med J 2010;104:902-10
11. Copher R, Cerulli A, Watkins A, et al. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ 2012;15:947-55
12. Said Q, Martin BC, Joish VN, et al. The cost to managed care of managing pulmonary hypertension. J Med Econ 2012;15:500-8
13. Hoyle M, Anderson R. Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making 2010;30:426-37
14. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003;158:915-20
15. Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95
16. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
17. Ventetuolo CE, Klinger Jr. WHO Group 1 pulmonary arterial hypertension: Current and investigative therapies. Prog Cardiovasc Dis 2012;55:89-103